Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours

Abstract

Background:Overexpression of ErbB2 receptor in breast cancer is associated with disease progression and poor prognosis. Trastuzumab, the only humanised anti-ErbB2 antibody currently used in breast cancer, has proven to be effective; however, a relevant problem for clinical practice is that a high fraction of breast cancer patients shows primary or acquired… (More)
DOI: 10.1038/sj.bjc.6605499

7 Figures and Tables

Topics

  • Presentations referencing similar topics